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provided it is propeObjective: This article compares trends in CD4þ T-cell recovery and proportions
achieving optimal restoration (500 cells/ml) after viral suppression following combi-
nation antiretroviral therapy (cART) initiation between rapid and nonrapid progressors.
Methods: We included HIV-1 seroconverters achieving viral suppression within 6
months of cART. Rapid progressors were individuals experiencing at least one CD4þ
less than 200 cells/ml within 12 months of seroconverters before cART. We used
piecewise linear mixed models and logistic regression for optimal restoration.
Results: Of 4024 individuals, 294 (7.3%) were classified as rapid progressors. At the
same CD4þ T-cell count at cART start (baseline), rapid progressors experienced faster
CD4þ T-cell increases than nonrapid progressors in first month [difference (95%
confidence interval) in mean increase/month (square root scale): 1.82 (1.61; 2.04)],
which reversed to slightly slower increases in months 1–18 [0.05 (0.06;0.03)] and
no significant differences in 18–60 months [0.003 (0.01; 0.01)]. Percentage achiev-
ing optimal restoration was significantly lower for rapid progressors than nonrapid
progressors at months 12 (29.2 vs. 62.5%) and 36 (47.1 vs. 72.4%) but not at month 60
(70.4 vs. 71.8%). These differences disappeared after adjusting for baseline CD4þ T-cell
count: odds ratio (95% confidence interval) 0.86 (0.61; 1.20), 0.90 (0.38; 2.17) and 1.56
(0.55; 4.46) at months 12, 36 and 60, respectively.
Conclusion: Among people on suppressive antiretroviral therapy, rapid progressors
experience faster initial increases of CD4þ T-cell counts than nonrapid progressors, but
are less likely to achieve optimal restoration during the first 36 months after cART,
mainly because of lower CD4þ T-cell counts at cART initiation.
Copyright  2015 Wolters Kluwer Health, Inc. All rights reserved.AIDS 2015, 29:2323–2333Carlos III, Madrid, Spain, bAthens University Medical School, Athens, Greece, cAIDS Research Institute
’Investigacio´ en Cie`ncies de la Salut Germans Trias i Pujol, Universitat Auto`noma de Barcelona, Badalona,
Department of Infection and Population Health, eMedical Research Council Clinical Trials Unit, University
ondon, UK, fInstitute of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy, gInserm,
search in Epidemiology and Population Health, Epidemiology of HIV and STI Team, Le Kremlin Bicetre, hUniv
lim Bicetre, iUPMC Univ Paris 06, jINSERM, Paris, France, kUniversitat de Vic-Central de Catalunya, UVIC-
stitucio´ Catalana de Recerca i Estudis Avanc¸ats (ICREA), Barcelona, Spain.
o Inma Jarrı´n, Instituto de Salud Carlos III, Madrid, Spain.
63; e-mail: ijarrin@isciii.es
d Javier Martinez-Picado are senior coauthors of this work.
l 2015; revised: 6 July 2015; accepted: 6 July 2015.
.0000000000000805
pyright Q 2015 Wolters Kluwer Health, Inc. All rights reserved. This is an open-access article distributed under the terms
mons Attribution-NonCommercial-NoDerivatives 4.0 License, where it is permissible to download and share the work
rly cited. The work cannot be changed in any way or used commercially. 2323
2324 AIDS 2015, Vol 29 No 17Introduction
Humans show a remarkable variation in clinical outcomes
following HIV-1 infection. Although some individuals
are able to control HIV replication for long periods (elite
controllers), others experience rapid CD4þ T-cell loss
after seroconversion (rapid progressors) in the absence of
combination antiretroviral therapy (cART) [1–2]. Over
the last few years, many studies have focused on these
extreme HIV phenotypes in a search for clues relating to
viral pathogenesis. Accumulating evidence suggests that a
combination of viral and host factors play a role in HIV
disease outcomes [3–7].
Rapid HIV progression is defined by a decay of CD4þ
T-cell counts below a threshold ranging between 100 and
350 cells/ml in a time frame from 6 months to 3 years [2,5]
after seroconversion. Studies of rapid progressors have been
limited by small numbers [7–9] and by the heterogeneityof
definitions used for rapid progressors. Both a documented
seroconversion date and a narrow seroconversion window
are generally required to characterize these uncommon
phenotypes. Indeed, Mun˜oz et al. [10] reported frequency
of the rapid progressors to be under 10% in the MACS, and
Rotger et al. [5] reported that approximately 8% of
seroconverters in the Swiss cohort were rapid progressors.
Recently, Olson et al. [2] showed that 2.8, 7.3 and 24.9% of
seroconverters in the Concerted Action of Seroconversion
to AIDS and Death in Europe (CASCADE) Collaboration
experienced at least one CD4þ cell count less than 100, 200
and 350 cells/ml, respectively, within 1 year of serocon-
verters.
Rapid progression could be clinically relevant for
immune restoration after cART initiation as poorer
CD4þ T-cell recovery has been associated with low
CD4þ T-cell counts at the initiation of therapy in a cross-
sectional study [11]. However, the link between rapid
progression and immune recovery is unknown.
The CASCADE Collaboration has previously reported
that individuals with steeper precART CD4þ T-cell
decline are more likely to experience greater CD4þ
T-cell increases after cART [12] but did not examine if
these responses varied among those who are virologically
suppressed. Several studies have revealed a substantial
prevalence of immunological nonresponders among
patients who are virologically suppressed on cART, with
rates ranging from 17 to 40%, depending on the study
criteria and the population [13–15]. Compared with
concordant responders (i.e. those with a good CD4þ
T-cell response while virally suppressed on cART), these
nonconcordant responders are at increased risk of clinical
progression to AIDS-related and non–AIDS-related
illnesses and death [11,13,16–23].
We hypothesized that rapid progression before cART
initiation predicts poor CD4þ T-cell recovery invirologically suppressed individuals and hinders optimal
CD4þ T-cell restoration. The objective of this analysis
was, therefore, to compare trends in CD4þ T-cell
recovery after cART initiation and the proportion
achieving counts at least 500 cells/ml after 12, 36 and
60 months between rapid and nonrapid progressors
achieving virological suppression.Methods
Ethics statement
All collaborating cohorts received approval from their
respective or national ethics review boards. Ethics
approval for CASCADE collaborating cohorts within
EuroCoord has been granted by the committees detailed
in the ‘Acknowledgements’ section.
Study population
We used data from CASCADE, updated in 2013 within
EuroCoord (www.EuroCoord.net), which consists of
29 884 individuals with well estimated dates of HIV
seroconversion (seroconverters) from 28 cohorts across
Europe, Canada, Australia and Sub-Saharan Africa [24].
Individuals followed-up in the two African cohorts
were excluded as both CD4þ T-cell count evolution
during natural history and treatment guidelines applied
to these populations differ from those in high-income
countries [25]. We also excluded individuals infected
through a route other than injecting drug use or sexual
intercourse (i.e. haemophilia, transfusion, other and
unknown) to avoid other clinical complications that
affect HIV disease progression. Eligible individuals were
patients initiating their first cART regimen from naive
and who achieved viral suppression (plasma HIV-RNA
level 200 copies/ml) within the first 6 months of
therapy and maintained it thereafter until their
censoring date. Patients had to have both CD4þ T-
cell counts and HIV-RNA measurements available at
start of cART (i.e. within the last 6 months prior to
cART initiation). Individuals with a viral load less than
1000 copies/ml at the time of starting cART were
excluded as they may have been misclassified as
treatment naı¨ve. Furthermore, to be able to classify
patients as rapid or nonrapid progressors, we required
that seroconversion dates were estimated in one of three
ways: as the midpoint between the last negative and first
positive HIV antibody test dates with an interval of less
than 12 months between tests, as the date of laboratory
evidence of acute seroconversion (PCR positivity in the
absence of HIV antibodies or antigen positivity with
fewer than four bands on Western blot), or as the date of
seroconversion illness for individuals with a test interval
of 12 months or less. Patients also had to have at least
one CD4þ T-cell count within the first 12 months of
seroconversion in the absence of antiretroviral therapy
(ART).
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at least one determination of CD4þT-cell counts less than
200 cells/ml within 12 months from seroconverters before
ART initiation, and as nonrapid progressors otherwise.
Additional definitions were also tested [2], and more
details are provided in the sensitivity analyses section.
Follow-up time started at cART initiation and was
censored at the first of the following dates: the first of two
consecutive occasions when the plasma HIV-RNA level
increased above 200 copies/ml (considered to be treat-
ment failure), the first of two consecutive HIV-RNA
measurements separated by more than 12 months
(considered to be lost to follow-up) or at the last date
when an HIV-RNA measurement was available within
60 months of starting therapy. Patients who modified
their cART regimens were not censored at date of
modification, provided plasma HIV-RNA levels
remained 200 copies/ml or less.
CART was defined as a protease inhibitor-based,
nonnucleoside reverse transcriptase inhibitor (NNRTI),
or fusion inhibitor-based regimen, in combination with
at least two nucleoside or nucleotide reverse transcriptase
inhibitors, or a triple nucleotide reverse transcriptase
inhibitor regimen including abacavir or tenofovir.
Statistical analysis
Differences in sociodemographic and clinical character-
istics between rapid and nonrapid progressors were
assessed through the nonparametric Mann–Whitney test
for continuous variables and the x2 test for independence
for categorical variables.
Trends in CD4þ T-cell counts after cART initiation were
modelled using a piecewise linear mixed-effects model
(to take into account the correlation between measure-
ments in the same individual) with three slopes (including
random effects for the intercept and the three slopes); the
best model (Akaike criterion) obtained allowed for
changes of slopes at months 1 and 18. The square root
transformation of the CD4þ T-cell counts was used to
fulfil the model assumptions.
As an initial approach, multivariable piecewise linear
mixed-effects models were initially adjusted for sex, age at
cART initiation, risk group (MSM, sex between men and
women, IDUs), geographical origin (non-sub-Saharan
Africa, migrants from sub-Saharan Africa, unknown)
used as a proxy for HIV subtype and log10 HIV-RNA
levels at cART initiation. However, as CD4þT-cell count
at cART initiation is known to be a strong predictor of
immunological outcome and is significantly lower in
rapid progressors, this initial approach was confounded by
the CD4þ T-cell counts at cART initiation. As
attempting to remove this confounding by including
the observed CD4þ T-cell counts at cART initiation as a
covariate in a model for later measurements is likely tointroduce bias, we used a method based on first following
the initial approach and then applying a correction to the
parameter estimates to compare rapid and nonrapid
progressors with the same underlying CD4þT-cell counts
at start of cART [26].
We calculated the proportion of patients who experi-
enced an optimal CD4þ T-cell restoration, defined as
achieving CD4þ T-cell counts of at least 500 cells/ml, at
12, 36 and 60 (3) months from cART initiation and
used logistic regression models to calculate odds ratios
(ORs) and 95% confidence intervals (CIs) for association
between rapid progressors status and optimal CD4þT-cell
count restoration. Multivariate logistic regression models
were initially adjusted for the same factors as in the
piecewise linear mixed-effects models, and additionally
adjusted for CD4þ T-cell count at cART initiation
(<100, 100–199, 200).
A set of sensitivity analyses was undertaken. Analyses were
repeated using 100 and 350 as CD4þ T-cell thresholds to
define rapid progressors; considering the first 6 months
from seroconverters to classify patients as rapid and
nonrapid progressors; defining an optimal CD4þ T-cell
restoration as achieving CD4þ T-cell counts of at least
600 cells/ml; restricting to individuals who started cART
with CD4þ T-cell counts less than 200 cells/ml; restrict-
ing to patients who started cART after year 2000 when
boosted protease inhibitors became widely available and
allowing patients to achieve viral suppression within the
first 12 months of therapy as patients with high viral loads
and those on protease inhibitor-based regimen may not
suppress by 6 months yet nonetheless by 12 months.
All statistical analyses were performed by using Stata
software (version 13.1; StataCorp, College Station, Texas,
USA).Results
Study population characteristics
Of 29 884 individuals, 25 860 were excluded from
analyses as follows: 916 followed-up in two African
cohorts, 1520 who were infected through a route other
than injecting drug use or sexual intercourse (157
haemophilia, 44 transfusion, 184 other and 1135
unknown), 9716 who never initiated cART, 5347 who
were ARTexperienced at cART initiation, 4009 who did
not achieve viral suppression within the first 6 months of
therapy, 691 as CD4þ T-cell count and/or HIV-RNA
measurements at cART initiation were not available, 485
who had a viral load at cART initiation less than
1000 copies/ml, 2680 for whom seroconversion date was
above 12 months after the last negative test and 496 as
CD4þ T-cell count within 12 months from seroconver-
ters in the absence of ART was not available.
2326 AIDS 2015, Vol 29 No 17Of 4024 individuals included in the analyses, 294 (7.3%)
were classified as rapid progressors, who were more likely
than nonrapid progressors to be women (17.7 vs. 11.2%),
infected through sex between men and women (30.9 vs.
18.2%), migrants originating from sub-Saharan Africa
(12.6 vs. 3.9%) and, when they subsequently started
cART, did so at with higher log10 HIV-RNA levels (5.1
vs. 4.8) and lower CD4þ T-cell counts (164 vs. 350)
(Table 1).
Trends in CD4R T-cell counts after combination
antiretroviral therapy initiation
A total of 40 893 CD4þ T-cell count measurements were
available post-cART initiation, 3451 among rapid
progressors and 37 442 among nonrapid progressors.
The median number of CD4þ T-cell counts measure-
ments per individual was 10 [interquartile range (IQR): 6;
16] for rapid progressors and 9 (IQR: 5; 14) for nonrapid
progressors with a median interval of 2.8 (IQR: 2.3; 3.5)
and 2.9 (2.2; 3.6) months between consecutive deter-
minations for rapid and non-rapid progressors, respec-
tively.
Median CD4þ T-cell count profiles for rapid and
nonrapid progressors, overall and among individuals
who started cART with CD4þ T-cell counts less than
200 cells/ml, are shown in Fig. 1. Unadjusted and adjusted
trends in CD4þ T-cell counts after cART initiation from
the piecewise linear mixed-effects model at 0–1, 1–18
and more than 18 months are given in Table 2. After
initial adjustment for sex, risk group, geographical origin,
age and log10 HIV-RNA level at cART initiation, rapid
progressors had faster initial and long-term CD4þ T-cell
increases than nonrapid progressors: differences in mean
CD4þ increase/month (square root scale) were 1.34 (95%
CI: 0.95; 1.72, P< 0.001) in 0–1 months, 0.03 (0.001;
0.05, P¼ 0.063) in 1–18 months and 0.04 (95% CI: 0.02;
0.06, P< 0.001) in 18–60 months. Applying the
postestimation adjustment procedure [26] to compare
rapid and nonrapid progressors with the same underlying
CD4þ T-cell counts at cART initiation, we found that
rapid progressors experienced a faster CD4þ T-cell
increase than nonrapid progressors in 0–1 months (1.82,
95% CI: 1.61; 2.04, P< 0.001), which reversed to slightly
slower increases in months 1–18 (0.05, 0.06; 0.03,
P< 0.001) and no significant differences in months 18–
60 (0.003, 95% CI: 0.01; 0.01, P¼ 0.62) (Table 2).
Figure 2a depicts the evolution of CD4þ T-cell counts for
rapid and nonrapid progressors MSM of 30 years of age, of
non-sub-Saharan African origin who started cART at 5
log10 HIV-1 RNA. It shows how rapid progressors, in
spite of steeper initial CD4þ T-cell counts increases, fail
to reach the threshold of 500 cells/ml until month 36.
Figure 2b illustrates the same changes comparing rapid
and nonrapid progressors who start cARTat CD4þ T-cell
count of 180 cells/ml. Figure 2b also shows rapid
progressors having steeper initial CD4þ T-cell countincreases but given that nonrapid progressors are now
‘forced’ to start cART at the same CD4þ T-cell count,
rapid progressors maintain higher values to month 60.
Analyses using 100 and 350 cells/ml as CD4þ T-cell
thresholds to define rapid progressors led to results
consistent with those of the main analyses although
differences in mean CD4þ increase/month between rapid
and nonrapid progressors were attenuated when con-
sidering 350 cells/ml as the CD4þ T-cell threshold.
Similar results were also obtained when the first 6 months
from seroconverters were used to classify patients as rapid
and nonrapid progressors, when analyses were restricted
to individuals who started cART after year 2000.
Restricting analyses to individuals who initiated cART
with CD4þ T-cell counts less than 200 cells/ml yielded
results similar to those obtained when using an adjustment
procedure [26]. Allowing patients to achieve viral
suppression within the first 12 months of therapy yielded
results consistent with those of the main analyses.
CD4R T-cell count restoration ( >– 500 cells/ml)
following suppressive combination antiretroviral
therapy
Among 4024 eligible patients, a total of 3092, 1379 and
484 were available for CD4þ T-cell analyses at 12, 36 and
60 months, respectively. Patients with missing data were
more likely than persons with available measurements to
be younger at cART initiation, infected through injecting
drug use and to have started cART in more recent years
with higher CD4þ T-cell counts. The percentage of
patients experiencing optimal restoration of CD4þ T-cell
counts of at least 500 cells/ml was significantly lower
among rapid than nonrapid progressors at months 12
(29.2 vs. 62.5%) and 36 (47.1 vs. 72.4%) but no
differences were found at month 60 (70.4 vs. 71.8%).
After initial adjustment for sex, risk group, geographical
origin, age and log10 HIV-RNA level at cART initiation,
rapid progressors remained less likely to achieve counts of
at least 500 cells/ml at months 12 (OR: 0.21, 95% CI:
0.13; 0.36, P< 0.001) and 36 (OR: 0.30, 95% CI: 0.11;
0.87, P¼ 0.03), a difference that disappeared at month 60
(OR: 0.79, 95% CI: 0.30; 2.09, P¼ 0.63). Additional
adjustment for CD4þ T-cell counts at cART initiation
(<100, 100–199, 200), however, showed no differ-
ences between rapid and nonrapid progressors at 12 (OR:
0.86, 95% CI: 0.61; 1.20, P¼ 0.36), 36 (OR: 0.90, 95%
CI: 0.38; 2.17, P¼ 0.82) or 60 months (OR: 1.56, 95%
CI: 0.55; 4.46, P¼ 0.40) (Table 3). Similar results were
obtained when using 600 as a cutoff to define optimal
CD4þ T-cell restoration (data not shown).
Analyses defining an optimal CD4þ T-cell restoration as
achieving CD4þ T-cell counts of at least 600 cells/ml led
to results consistent with those of the main analyses. In
addition, performing the other procedures of sensitivity
analyses mentioned earlier yielded results consistent with
those of the main analysis (data not shown).
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Table 1. Sociodemographic and clinical characteristics at start of combination antiretroviral therapy for 4024 individuals by precombination
antiretroviral therapy progressor status.
Nonrapid progressors Rapid progressors
P value3730 (92.7) 294 (7.3)
Sex 0.001
Men 3312 (88.8) 242 (82.3)
Women 418 (11.2) 52 (17.7)
Age at cART (years)
Median (IQRa) 36 (30; 42) 35 (29; 42) 0.66
<30 928 (24.9) 74 (25.2) 0.89
30–39 1501 (40.2) 122 (41.5)
40–49 887 (23.8) 64 (21.8)
50 414 (11.1) 34 (11.6)
Transmission category <0.001
Sex between men 2887 (77.4) 187 (63.6)
Sex between men and women 679 (18.2) 91 (31.0)
IDU 164 (4.4) 16 (5.4)
Geographical origin <0.001
Non sub-Saharan Africa 2729 (73.2) 195 (66.3)
Migrants from sub-Saharan Africa 145 (3.9) 37 (12.6)
Unknown 856 (22.9) 62 (21.1)
Ethnic group 0.001
White 1800 (48.3) 118 (40.1)
Black 111 (2.9) 17 (5.8)
Other 45 (1.2) 8 (2.7)
Unknown 1774 (47.6) 151 (51.4)
Higher education ever attained 0.001
Preprimary or primary education 88 (2.4) 13 (4.4)
Secondary education 527 (14.1) 45 (15.3)
Postsecondary education 503 (13.5) 18 (6.1)
Unknown 2612 (70.0) 218 (74.2)
Acute infectionb 0.11
No 2504 (67.1) 184 (62.6)
Yes 1226 (32.9) 110 (37.4)
Date of SC [median (IQRa)] 05 March (00 December; 08 June) 05 August (02 March; 08 September) 0.04
Date of cART initiation [median (IQRa)] 08 February (03 March; 10 July) 06 September (02 November; 09 June) <0.001
cART based on 0.48
NNRTI 1656 (44.4) 120 (40.8)
PI 1544 (41.4) 128 (43.5)
3 class/other 530 (14.2) 46 (15.7)
CD4þ T-cell counts at cART (cells/ml)
Median (IQRa) 350 (270; 473) 164 (120; 196) <0.001
<200 276 (7.4) 234 (79.6) <0.001
200–350 1602 (42.9) 53 (18.0)
>350 1852 (49.7) 7 (2.4)
Log10 HIV-RNA at cART initiation
Median (IQRa) 4.8 (4.3–5.3) 5.1 (4.6–5.7) <0.001
<4 502 (13.5) 26 (8.8) <0.001
4–5 1728 (46.3) 102 (34.7)
>5 1500 (40.2) 166 (56.5)
AIDS diagnosis at cART 0.005
No 3589 (96.2) 272 (92.5)
Yes 137 (3.7) 22 (7.5)
Unknown 4 (0.1) 0
Hepatitis C virus antibodies at cART 0.93
No 2013 (54.0) 160 (54.4)
Yes 163 (4.4) 14 (4.8)
Unknown 1554 (41.6) 120 (40.8)
Hepatitis B surface antigen 0.47
No 1949 (52.2) 159 (54.1)
Yes 73 (2.0) 3 (1.0)
Unknown 1708 (45.8) 132 (44.9)
Time from SC to cART initiation (months)
Median (IQRa) 16 (4; 38) 6 (3; 9) <0.001
<6 1118 (30.0) 142 (48.3) <0.001
6–12 507 (13.6) 106 (36.0)
12 2105 (56.4) 46 (15.7)
cART, combination antiretroviral therapy; IQR, interquartile range; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor;
SC, seroconversion.
bAcute infection is defined as having laboratory evidence of acute seroconversion or an HIV test interval of less than 30 days.
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Fig. 1. Observed CD4R T-cell counts in rapid and nonrapid
progressors. (a) All patients. (b) Patients starting combination
antiretroviral therapy with CD4þ T-cell counts less than
200 cells/ml.
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.Discussion
Rapid progression prior to cART initiation hinders
optimal CD4þ T-cell recovery once HIV-1 suppressive
response to cART is achieved. Although rapid progressors
experience faster initial increases in CD4þ T-cells than
nonrapid progressors, they are less likely to achieve CD4þ
T-cell counts of at least 500 cells/ml during the first 36
months after cART. These outcomes are largely explained
by their lower CD4þ T-cell counts at cART initiation.
Our current work builds on previous work conducted by
the CASCADE Collaboration showing that individuals
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Fig. 2. Predicted CD4R T-cell counts in rapid and nonrapid
progressors. (a) From an initial piecewise linear mixed model
(men,MSM, non-SSA, 30 years old at start of cART and 5 log10
HIV-RNA level at cART initiation). (b) After the postestimation
adjustment procedure (men, MSM, non-SSA, 30 years old at
start of cART, 5 log10 HIV-RNA level at cART initiation and an
underlying CD4þ T-cell count at cART initiation of 180 cells/
ml). cART, combination antiretroviral RP, rapid progressors;
SSA, sub-Saharan Africa.with a faster rate of CD4þ T-cell loss precART tended to
experience faster immune reconstitution once they
started cART, independently of baseline CD4þ T-cell
count and plasma HIV-RNA value [12]. We show that
rapid progressors who achieve suppressive response to
cART experience delays in achieving optimal CD4þ
count recovery during the first 36 months after cART,
which puts them at a higher risk of developing
immunodeficiency-related complications. That this
may happen in a nonnegligible proportion of the
population is of concern. In our study, 7.3% of HIV-1
seroconverters fulfilled the criteria of rapid progression, asimilar percentage to that previously reported in other
studies [2,5,10], although study populations were not
strictly comparable.
When comparing the outcomes of these rapid progressors
with patients whose progression was not rapid, but whose
CD4þT-cell count at cARTwas similar, the differences in
CD4þ T-cell responses largely disappeared. Nevertheless,
steeper CD4þ T-cell responses were still experienced by
the rapid progressors suggesting that a prior faster decline
may allow mounting enhanced responses. It could be that
the rapid loss of CD4þ T cells from the peripheral blood
observed in rapid progressors is secondary to cell
redistribution in lymph nodes in a higher proportion
than in nonrapid progressors, as well as to cellular death.
Thus, recovery is bound to be more rapid once HIV viral
replication is suppressed and thus the cause of the
redistribution is eliminated [27,28]. This suggests that not
only the absolute CD4þ T-cell value but also the time to
reach that value influences responses to cART in virally
suppressed individuals; cART may elicit better CD4þ
T-cell responses in a time window before deep
immunological damage has been caused.
These data confirm the potency of current cARTregimes
in their ability to reduce viremia and thus facilitate
subsequent immune recovery of CD4þ T cells, even
among those who had experienced rapid progression to
low CD4þ count prior to starting cART. However, the
similar dynamics in the recovery of CD4þT cells after the
first month of therapy prevents rapid progressors from
fully recovering from their profound initial loss of cells.
This study has some limitations. First, the high proportion
of patients with missing data made it difficult to assess
CD4þ T-cell count restoration at 12, 36 and, especially,
60 months after cART initiation. However, as missingness
appeared not related to status of the rapid progressors,
there is no reason to believe that this should influence our
results. Second, in 3.7% of seroconverters (1.7% in rapid
progressors and 3.8% in nonrapid progressors), serocon-
version date was estimated as the date of seroconversion
illness, which has been associated with faster disease
progression [29]. However, in sensitivity analyses
excluding these patients, results were consistent with
those of the main analyses. Third, although our work is
based on HIV-1 seroconverters who are unlikely to be
comparable with the general HIV-infected population in
a number of ways, it has been recently shown that there
are no major differences in HIV disease progression
between seroconverters and seroprevalent individuals [30]
suggesting that our results are generalizable to the HIV-
positive population.
Our findings have implications for public health policy,
clinical management and basic science research. Ideally,
cART should be started as soon as possible after HIV-1
diagnosis regardless of the CD4 T-cell count (START
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Table 3. CD4R T-cell count restoration at 12, 36 and 60 months from combination antiretroviral therapy initiation.
N
N (%) CD4þ
cell count 500
Unadjusted analyses
Adjusted analyses
Model 1a
Model 1 þ CD4þ
at cART initiationb
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
12 months Nonrapid progressors 2852 1782 (62.5) 1.00 1.00 1.00
Rapid progressors 240 70 (29.2) 0.25 (0.14; 0.42) <0.001 0.21 (0.13; 0.36) <0.001 0.86 (0.61; 1.20) 0.36
36 months Nonrapid progressors 1260 912 (72.4) 1.00 1.00 1.00
Rapid progressors 119 56 (47.1) 0.34 (0.11; 1.05) 0.06 0.30 (0.11; 0.87) 0.03 0.90 (0.38; 2.17) 0.82
60 months Nonrapid progressors 440 316 (71.8) 1.00 1.00 1.00
Rapid progressors 44 31 (70.4) 0.94 (0.37; 2.36) 0.89 0.79 (0.30; 2.09) 0.63 1.56 (0.55; 4.46) 0.40
CI, confidence interval; cART, combination antiretroviral therapy; OR, odds ratio.
aAdjusted for sex, age at cART initiation, risk group (MSM, sex between men and women, IDUs), geographical origin (migrants from sub-Saharan
Africa, non-sub-Saharan Africa, unknown) used as a proxy of subtype and log10 HIV-RNA levels at cART initiation.
bAdjusted for sex, age at cART initiation, risk group (MSM, sex betweenmen andwomen, IDUs), geographical origin (sub-Saharan Africa, non-sub-
Saharan Africa, unknown) used as a proxy of subtype, log10 HIV-RNA levels at cART initiation andCD4
þ T cells at cART initiation (<100, 100–199,
200 cells/ml).study: http://www.niaid.nih.gov/news/newsreleases/
Archive/2011/Pages/START.aspx).
However, in clinical settings wherein cART is not widely
available, our results would support strategies that
promote frequent testing to reduce the proportion of
patients initiating cART at low CD4þ T-cell counts,
which is largely secondary to delayed HIV-1 diagnoses.
For those testing early, we suggest frequent CD4þ T-cell
count monitoring close to the time of HIV diagnoses to
establish the rapid progressors phenotype in order to
avoid unnecessary CD4þ T-cell count decay among rapid
progressors. Finally, elucidating the immunopathological
bases of rapid progression should help to improve
individual clinical outcome and limit its impact in the
global HIV-1 pandemics.Acknowledgements
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